A Phase Ib, Multi-Center, Randomized, Observer-Blind, Proof of Concept, Dose- and Formulation-Ranging Study to Evaluate Safety, Tolerability, and Immunogenicity of One Dose of Trivalent Inactivated Influenza Vaccine in Different Presentations (Intramuscular and Intradermal Delivery), Dosages (Regular or Higher A/H3N2 Content) and Doses of Adjuvant Administered to Healthy Elderly Aged greater than or equal to 65 Years.
Phase of Trial: Phase I
Latest Information Update: 11 May 2016
At a glance
- Drugs Influenza virus vaccine; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Seqirus
- 24 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Feb 2009 New trial record